

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

DECLARATION AND POWER OF ATTORNEY

In re Application of: Jean-Pierre Sommadossi and Paulo LaColla

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name. I believe I am a original, first and sole inventor (OR a original, first and joint inventor) of the subject matter which is claimed and for which a patent is sought on the invention entitled: "*Methods and Compositions for Treating Hepatitis C Virus*," the specification of which was filed with the U.S. Patent and Trademark Office on May 23, 2001 as U.S. Application No. 09/864,078.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I do not know and do not believe that the same was ever known or used by others in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to the date of this application. I further state that the invention was not in public use or on sale in the United States of America more than one year prior to the date of this application. *I understand that I have a duty of candor and good faith toward the Patent and Trademark Office*, and I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of the foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate disclosing subject matter in common with the above-identified specification and having a filing date before that of the application on which priority is claimed:

<u>Application No.</u>	<u>Country</u>	<u>Filing Date</u>	<u>Priority Claimed Under 35 USC §119</u>
<u>None</u>			

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

<u>60/206,585</u>	<u>May 23, 2000</u>		
(Application No.)	(Filing Date)	(Application No.)	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter disclosed and claimed in the present application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:


<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>
<u>None</u>		

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statement were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.

POWER OF ATTORNEY: The following are hereby appointed to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Sherry M. Knowles-33,052; W. Scott Petty-35,645; Clark G. Sullivan-36,942; Holmes J. Hawkins-38,913; Steven P. Wigmore-40,447; Lisa K. Norton-44,977; Charles E. Peeler-45,004; Joseph M. Bennett-Paris-47,226; Shane A. Nichols-43,836; Bob Neufeld-P-48,394; Josephine Young P-48,308; Bill Isaacs-44,165.

Send correspondence to: Sherry M. Knowles
King & Spalding
191 Peachtree Street, N.E., 45th Floor
Atlanta, Georgia 30303

Direct telephone calls at (404) 572-4600
Sherry M. Knowles

Full name of joint inventor: Jean Pierre Sommadossi	Citizenship: FR
Inventor's signature: 	Date: 6/21/01
Residence and Post Office Address: 5075 Greystone Way, Birmingham, AL 3524 US	

DECLARATION AND POWER OF ATTORNEY

In re Application of: Jean-Pierre Sommadossi and Paulo LaColla

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name. I believe I am a original, first and sole inventor (OR a original, first and joint inventor) of the subject matter which is claimed and for which a patent is sought on the invention entitled: "*Methods and Compositions for Treating Hepatitis C Virus*," the specification of which was filed with the U.S. Patent and Trademark Office on May 23, 2001 as U.S. Application No. 09/864,078.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I do not know and do not believe that the same was ever known or used by others in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to the date of this application. I further state that the invention was not in public use or on sale in the United States of America more than one year prior to the date of this application. *I understand that I have a duty of candor and good faith toward the Patent and Trademark Office*, and I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of the foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate disclosing subject matter in common with the above-identified specification and having a filing date before that of the application on which priority is claimed:

<u>Application No.</u>	<u>Country</u>	<u>Filing Date</u>	<u>Priority Claimed Under 35 USC §119</u>
None			

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

<u>60/206,585</u>	<u>May 23, 2000</u>		
(Application No.)	(Filing Date)	(Application No.)	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter disclosed and claimed in the present application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:


<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>
None		

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statement were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.

POWER OF ATTORNEY: The following are hereby appointed to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Sherry M. Knowles-33,052; W. Scott Petty-35,645; Clark G. Sullivan-36,942; Holmes J. Hawkins-38,913; Steven P. Wigmore-40,447; Lisa K. Norton-44,977; Charles E. Peeler-45,004; Joseph M. Bennett-Paris-47,226; Shane A. Nichols-43,836; Bob Neufeld-P-48,394; Josephine Young P-48,308; Bill Isaacs-44,165.

Send correspondence to: Sherry M. Knowles
King & Spalding
 191 Peachtree Street, N.E., 45th Floor
 Atlanta, Georgia 30303

Direct telephone calls at (404) 572-4600
 Sherry M. Knowles

Full name of joint inventor: Paulo LaColla	Citizenship: IT
Inventor's signature: 	Date: 20 JUNE 2001
Residence and Post Office Address: 5 Strada no. 11, Poggio dei Pini, 09012 Capoterra, Cagliari Italy	




OCTOBER 28, 2002

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GA 30303-1763



102199601A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/19/2002

REEL/FRAME: 013193/0841
NUMBER OF PAGES: 4

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
NOVIRIO PHARMACEUTICALS LIMITED

DOC DATE: 05/28/2002

ASSIGNEE:
IDENIX PHARMACEUTICALS INC.
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

SERIAL NUMBER: 60132126
PATENT NUMBER:

FILING DATE: 04/30/1999
ISSUE DATE:

SERIAL NUMBER: 60096110
PATENT NUMBER:


FILING DATE: 08/10/1998
ISSUE DATE:

SERIAL NUMBER: 60131352
PATENT NUMBER:

FILING DATE: 04/28/1999
ISSUE DATE:

SERIAL NUMBER: 10022276
PATENT NUMBER:

FILING DATE: 12/14/2001
ISSUE DATE:



013193/0841 PAGE 2

SERIAL NUMBER: 09459150
PATENT NUMBER: 6444652

SERIAL NUMBER: 10022148
PATENT NUMBER:

SERIAL NUMBER: 09744038
PATENT NUMBER:

SERIAL NUMBER: 60207538
PATENT NUMBER:

SERIAL NUMBER: 09867110
PATENT NUMBER:

SERIAL NUMBER: 60212100
PATENT NUMBER:

SERIAL NUMBER: 09883033
PATENT NUMBER:

SERIAL NUMBER: 60207674
PATENT NUMBER:

SERIAL NUMBER: 60283276
PATENT NUMBER:

SERIAL NUMBER: 09863816
PATENT NUMBER:

SERIAL NUMBER: 60206585
PATENT NUMBER:

SERIAL NUMBER: 09864078
PATENT NUMBER:

SERIAL NUMBER: 60283393
PATENT NUMBER:

SERIAL NUMBER: 10122252
PATENT NUMBER:

SERIAL NUMBER: 60249532
PATENT NUMBER:

SERIAL NUMBER: 10001868
PATENT NUMBER:

SERIAL NUMBER: 60326184
PATENT NUMBER:

SERIAL NUMBER: 60326192
PATENT NUMBER:

FILING DATE: 12/10/1999
ISSUE DATE: 09/03/2002

FILING DATE: 12/14/2001
ISSUE DATE:

FILING DATE: 05/01/2001
ISSUE DATE:

FILING DATE: 05/26/2000
ISSUE DATE:

FILING DATE: 05/29/2001
ISSUE DATE:

FILING DATE: 06/15/2000
ISSUE DATE:

FILING DATE: 06/15/2001
ISSUE DATE:

FILING DATE: 05/26/2000
ISSUE DATE:

FILING DATE: 04/11/2001
ISSUE DATE:

FILING DATE: 05/23/2001
ISSUE DATE:

FILING DATE: 05/23/2000
ISSUE DATE:

FILING DATE: 05/23/2001
ISSUE DATE:

FILING DATE: 04/11/2001
ISSUE DATE:

FILING DATE: 04/11/2002
ISSUE DATE:

FILING DATE: 11/17/2000
ISSUE DATE:

FILING DATE: 11/19/2001
ISSUE DATE:

FILING DATE: 09/28/2001
ISSUE DATE:

FILING DATE: 09/28/2001
ISSUE DATE:

013193/0841 PAGE 3

SERIAL NUMBER: 09371747
PATENT NUMBER: 6395716

FILING DATE: 08/10/1999
ISSUE DATE: 05/28/2002

PAULA MCCRAY, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



UNITED STATES
PATENT AND
TRADEMARK OFFICE

JUNE 11, 2003

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GA 30303-1763



102359457A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/06/2003

REEL/FRAME: 013718/0543
NUMBER OF PAGES: 7

BRIEF: CERTIFICATE OF DOMESTICATION INCORPORATION IN DELAWARE

ASSIGNOR:

NOVIRIO PHARMACEUTICALS LIMITED

DOC DATE: 05/30/2002

ASSIGNEE:

IDENIX PHARMACEUTICALS INC.
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

SERIAL NUMBER: 60096110
PATENT NUMBER:

FILING DATE: 08/10/1998
ISSUE DATE:

SERIAL NUMBER: 60131352
PATENT NUMBER:

FILING DATE: 04/28/1999
ISSUE DATE:

SERIAL NUMBER: 10022276
PATENT NUMBER: 6569837

FILING DATE: 12/14/2001
ISSUE DATE: 05/27/2003

SERIAL NUMBER: 10022148
PATENT NUMBER: 6566344

FILING DATE: 12/14/2001
ISSUE DATE: 05/20/2003

SERIAL NUMBER: 60207538
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 09867110
PATENT NUMBER:

FILING DATE: 05/29/2001
ISSUE DATE:

SERIAL NUMBER: 60212100
PATENT NUMBER:

FILING DATE: 06/15/2000
ISSUE DATE:

SERIAL NUMBER: 09883033
PATENT NUMBER:

FILING DATE: 06/15/2001
ISSUE DATE:

SERIAL NUMBER: 60207674
PATENT NUMBER:

FILING DATE: 05/26/2000
ISSUE DATE:

SERIAL NUMBER: 60283276
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 09863816
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60206585
PATENT NUMBER:

FILING DATE: 05/23/2000
ISSUE DATE:

SERIAL NUMBER: 09864078
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

SERIAL NUMBER: 60283393
PATENT NUMBER:

FILING DATE: 04/11/2001
ISSUE DATE:

SERIAL NUMBER: 10122252
PATENT NUMBER:

FILING DATE: 04/11/2002
ISSUE DATE:

SERIAL NUMBER: 60249532
PATENT NUMBER:

FILING DATE: 11/17/2000
ISSUE DATE:

SERIAL NUMBER: 10001868
PATENT NUMBER: 6545007

FILING DATE: 11/19/2001
ISSUE DATE: 04/08/2003

SERIAL NUMBER: 60326184
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 60326192
PATENT NUMBER:

FILING DATE: 09/28/2001
ISSUE DATE:

SERIAL NUMBER: 09371747
PATENT NUMBER: 6395716

FILING DATE: 08/10/1999
ISSUE DATE: 05/28/2002

SERIAL NUMBER: 09459150
PATENT NUMBER: 6444652

FILING DATE: 12/10/1999
ISSUE DATE: 09/03/2002

013718/0543 PAGE 3

SAUNDRA BALLENGER, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

02-07-2003



102359457

FORM-PTO-1595
1-31-92TRANSMITTAL OF DOCUMENT FOR RECORDATION
PATENTS ONLY

Atty. Docket 06171.105004

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Novirio
Pharmaceuticals Limited
Additional name(s) of conveying party(ies) attached?
☐ Yes ☒ No

3. Nature of Conveyance:
☐ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☒ Other Certificate of Domestication:
incorporation in Delaware
Execution Date: 5/30/02

2. Name and address of receiving party(ies):

Name: Idenix Pharmaceuticals Inc.

Foreign Address:

Domestic Address: 125 Cambridge Park Dr.City: Cambridge State: MA ZIP: 02140

Additional name(s) & address(es) attached?

☐ Yes ☒ No

4. Application number (s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B Patent Registration No. (s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sherry M. Knowles, Esq.191 Peachtree StreetAtlanta, Georgia 30303-1763Telephone No.: 404- 572- 4600Facsimile No.: 404 572-51006. Number of applications and patents involved:
227. Total fee (37 CFR 3.41): \$ 880☒ Enclosed☐ Authorized to be charged to deposit account

8. Deposit account number

11-0980

(Attach duplicate copy of this page if paying by deposit account):

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy of the original document.

Sally Sexton

Name of Person Signing

Signature

January 30, 2003

Date

Total number of pages comprising cover sheet: 3

02/07/2003 ECOOPER 00000082 60096110

01 FC:6021

880.00 OP

OFFICE OF PUBLIC RECORDS

FINANCE SECTION
2003 FEB -6 PM 3:03

Idenix Pharmaceuticals Patent Docket

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX 1000 Provisional β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/98	60/096,110		
	CON	04/28/99	60/131,352		
IDX 1000 Normal β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	8/10/99	09/371,747	6,395,716	5/28/02
IDX 1000CON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,276		
IDX/1000 CIP β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/10/99	09/459,150	6,444,652	9/3/02
IDX 1000 CIPCON β -L-2'-Deoxy- Nucleosides for the Treatment of Hepatitis B	U.S.	12/14/01	10/022,148		
IDX 1004 Methods for Treating Hepatitis Delta Virus Infection with β - L-2' Deoxy-Nucleosides	U.S. Prov.	5/29/00	60/207,538		
	U.S.	5/29/01	09/867,110		
IDX 1005 3'-Prodrugs of 2'-deoxy- β -L- Nucleosides	U.S. Prov.	6/15/00	60/212,100		
	U.S.		09/883,033		
IDX1006 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	5/26/00 4/11/01	60/207,674 60/283,276		
	U.S.	5/26/01	09/863,816		
IDX1007 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	05/23/00	60/206,585		
	U.S.	05/23/01	09/864,078		
IDX1008 Phenylindoles For The Treatment Of HIV	U.S. Prov.	4/11/01	60/283,393		
	U.S.	4/11/02	10/122,252		

TITLE & DOCKET NAME	COUNTRY	FILING DATE	SERIAL NUMBER	PATENT NUMBER	ISSUE DATE
IDX1009 Methods for Inhibiting the Transmission of HIV Using Topically Applied Substituted 6-Benzyl-4- Oxopyrimidines	U.S. Prov.	11/17/00	60/249,532		
	U.S.	11/19/01	10/001,868		
IDX1013 Methods and Compositions for Treating Hepatitis C Virus	U.S. Prov.	9/28/01	60/326,184		
IDX1014 Methods and Compositions for Treating Flaviviruses and Pestiviruses	U.S. Prov.	9/28/01	60/326,192		

FROM

(THU) 5.30' 02 7:59/ST.

STATE OF DELAWARE
DIVISION OF CORPORATIONS
FILED 08:00 AM 05/30/2002
020342271 - 3530324

CERTIFICATE OF DOMESTICATION
OF
IDENIX PHARMACEUTICALS, INC.

It is hereby certified that:

1. Idenix Pharmaceuticals, Inc. (hereinafter called the "corporation") was first formed, incorporated, or otherwise came into being on May 1, 1998 in the jurisdiction of the Cayman Islands.
2. The name of the corporation immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
3. The name of the corporation as set forth in its certificate of incorporation to be filed concomitantly with this certificate of domestication in accordance with subsection (b) of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
4. The jurisdiction that constituted the seat, siege social, or principal place of business or central administration of the corporation, or other equivalent thereto under applicable law immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is the jurisdiction of the Cayman Islands.
5. The undersigned is a corporation, officer, director, trustee, manager, partner, or other person performing functions equivalent to those of an officer or director, however named or described, and is authorized to sign this certificate of domestication on behalf of the corporation.
6. This certificate of domestication shall be effective at 9:00 a.m. on May 30, 2002.

Dated: May 30, 2002

/s/ Jean-Pierre Sommadossi


Jean Pierre-Sommadosi
Chief Executive Officer,
Idenix Pharmaceuticals, Inc.

CERTIFICATE OF DOMESTICATION
OF
IDENIX PHARMACEUTICALS, INC.

It is hereby certified that:

1. Idenix Pharmaceuticals, Inc. (hereinafter called the "corporation") was first formed, incorporated, or otherwise came into being on May 1, 1998 in the jurisdiction of the Cayman Islands.
2. The name of the corporation immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
3. The name of the corporation as set forth in its certificate of incorporation to be filed concomitantly with this certificate of domestication in accordance with subsection (b) of Section 388 of the General Corporation Law of the State of Delaware is Idenix Pharmaceuticals, Inc.
4. The jurisdiction that constituted the seat, siege social, or principal place of business or central administration of the corporation, or other equivalent thereto under applicable law immediately prior to the filing of this certificate of domestication pursuant to the provisions of Section 388 of the General Corporation Law of the State of Delaware is the jurisdiction of the Cayman Islands.
5. The undersigned is a corporation, officer, director, trustee, manager, partner, or other person performing functions equivalent to those of an officer or director, however named or described, and is authorized to sign this certificate of domestication on behalf of the corporation.
6. This certificate of domestication shall be effective at 9:00 a.m. on May 30, 2002.

Dated: May 30, 2002



Jean Pierre-Sommadossi
Chief Executive Officer,
Idenix Pharmaceuticals, Inc.

Registrar of Companies,
Tower Building,
Grand Cayman.

Dear Sir,

IDENIX PHARMACEUTICALS, INC.

I, Andrea J. Corcoran, of 61 Garfield Street, Cambridge, MA 0218, being a director of Idenix Pharmaceuticals, Inc. (the "Company"), an exempted company incorporated under the Companies Law (2001 Second Revision), DO HEREBY make application, pursuant to Section 226 of the Companies Law (2001 Second Revision) for the Company to be deregistered in the Cayman Islands.


In support of this application:

1. I would advise that the Company has been accepted for domestication pursuant to Section 388 of the General Corporation Law of the State of Delaware, the United States of America. A copy of the Certificate of Domestication is attached to this application. I confirm that the laws of the State of Delaware, the United States of America permit the transfer of the Company to that jurisdiction and indeed that is the effect of the domestication procedure.
2. I enclose payment of US\$2,414.63 (CI\$1980) in respect of the fee for deregistration.
3. I confirm that the Company does not propose to change its name following deregistration.
4. I confirm that the Company has no secured creditors.
5. I confirm that the Company is not and has never been licensed under the provisions of the Banks and Trust Companies Law, (2001 Revision) or the Insurance Law, (2001 Revision).

I attach to this application

1. a certified copy of the Special Resolution of the Company adopted on ____ May 2002 resolving to register the Company by way of continuation in the State of Delaware, the United States of America;
2. a certified copy of the Resolution adopted by the Board of Directors of the Company dated May 6, 2002 resolving to apply for deregistration pursuant to Section 226 of the Companies Law (2001 Second Revision) and authorising me to make this application on behalf of the Company; and
3. my affidavit in support of this application in the terms prescribed by section 226(3) of the Companies Law (2001 Second Revision).


DATED this day of May 2002


Andrea J. Corcoran
Director

IDENIX PHARMACEUTICALS, INC.

CERTIFICATE OF MAILING (37 CFR § 1.8a)

I hereby certify that this Recordation of Assignment, along with any other paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Box Assignment, Commissioner for Patents, Washington, D.C. 20231.



Sally Sexton

06171.105004
Date: January 30, 2003

Delaware


PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DOMESTICATION OF "IDENIX PHARMACEUTICALS, INC.", FILED IN THIS OFFICE THE THIRTIETH DAY OF MAY, A.D. 2002, AT 8 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF DOMESTICATION IS THE THIRTIETH DAY OF MAY, A.D. 2002, AT 9 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

3530324 8100D

020342271

AUTHENTICATION: 1802262

DATE: 05-30-02



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

NOVEMBER 19, 2001

PTAS

SHERRY M. KNOWLES, ESQ.
191 PEACHTREE STREET
ATLANTA, GA 30303-1763



101848297A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 09/13/2001

REEL/FRAME: 012162/0294
NUMBER OF PAGES: 6

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
SOMMADOSSI, JEAN PIERRE

DOC DATE: 06/25/2001

ASSIGNOR:
LACOLLA, PAOLA


DOC DATE: 06/20/2001

ASSIGNEE:
NOVIRIO PHARMACEUTICALS LIMITED
125 CAMBRIDGE PARK DR.
CAMBRIDGE, MASSACHUSETTS 02140

ASSIGNEE:
UNIVERSITA DEGLI STUDI DI CAGLIARI
CITTADELLA UNIVERSITARIA SS 554,
KM. 4.500
09042 MONSERRATO (CA), ITALY

SERIAL NUMBER: 60206585
PATENT NUMBER:

FILING DATE: 05/23/2000
ISSUE DATE:



012162/0294 PAGE 2

SERIAL NUMBER: 09864078
PATENT NUMBER:

FILING DATE: 05/23/2001
ISSUE DATE:

MARY BENTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

09-19-2001

FORM-PTO-1595
1-31-92

TRAN:

101848297
PATENTS ONLY

RDATION

Atty. Docket 06171.105009

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Jean Pierre
Sommadosi and Paolo LaColla

Additional name(s) of conveying party(ies) attached?

☐ Yes☒ No

3. Nature of Conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name

Other

Execution Date: 6/20/01 and 6/25/01

2. Name and address of receiving party(ies):

Name: Novirio Pharmaceuticals LimitedForeign Address: c/o Walker Secretaries, Walker
House, Mary Street, Grand Cayman, Cayman IslandsDomestic Address: 125 Cambridge Park Dr.City: Cambridge State: MA ZIP: 02140

Additional name(s) & address(es) attached?

☒ Yes ☐ No

4. Application number (s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is:

SEP 13 2001

A. Patent Application No.(s) 60/206,585 and 09/864,078

B Patent Registration No. (s)

Additional numbers attached ? ☐ Yes ☒ No5. Name and address of party to whom correspondence
concerning document should be mailed:Name: Sherry M. Knowles, Esq.191 Peachtree StreetAtlanta, Georgia 30303-1763Telephone No.: 404- 572- 4600Facsimile No.: 404 572-5100

6. Number of applications and patents involved:

two

7. Total fee (37 CFR 3.41): \$ 80☒ Enclosed☐ Authorized to be charged to deposit account

8. Deposit account number

11-0980

(Attach duplicate copy of this page if paying by deposit account):

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy
of the original document.*

Sally Sexton

Name of Person Signing

Signature

September 10, 2001

Date

Total number of pages comprising cover sheet: 2

09/18/2001 TDI A21 00000105 60206585

01 FC:581

80.00 OP

Second Applicant:

Universita Degli Studi Di Cagliari
Cittadella Universitaria SS 554, Km. 4.500
09042 MONSERRATO (CA), Italy

ASSIGNMENT


WHEREAS, WE, JEAN-PIERRE SOMMADOSSI AND PAULO LACOLLA have invented certain improvements in "*Methods and Compositions for Treating Hepatitis C Virus*" for which I have executed United States provisional application no. 60/206,585 which was filed on May 23, 2000 and U.S. Application No. 09/864,078 which was filed on May 23, 2001; and

WHEREAS, NOVIRIO PHARMACEUTICALS LIMITED, a Cayman Island corporation having an office at c/o Walker Secretaries, Walker House, Mary Street, Grand Cayman, Cayman Islands desires to purchase same;


NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by NOVIRIO PHARMACEUTICALS LIMITED, the receipt and sufficiency of which are hereby acknowledged, I, JEAN-PIERRE SOMMADOSSI, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto NOVIRIO PHARMACEUTICALS LIMITED, in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 25 day of

June, 2001.


JEAN-PIERRE SOMMADOSSI

On this 25th day of June, 2001, before me, a notary public, came Jean-Pierre Sommadossi to me known and known to be the individual described in and who executed the foregoing assignment, and he duly acknowledged the same to be his free act and deed.


Notary Public

(SEAL)

My commission expires: CYNTHIA B. GAGNE
Notary Public
My Comm. Expires Sept. 25, 2003

ASSIGNMENT

WHEREAS, WE, JEAN-PIERRE SOMMADOSSI AND PAULO LACOLLA have invented certain improvements in "*Methods and Compositions for Treating Hepatitis C Virus*" for which I have executed United States provisional application no. 60/206,585 which was filed on May 23, 2000 and U.S. Application No. 09/864,078 which was filed on May 23, 2001; and

WHEREAS, **Universita Degli Studi Di Cagliari**, with a mailing address of Cittadella Universitaria SS 554, Km. 4.500, 09042 MONSERRATO (CA), Italy desires to purchase same;


NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by **Universita Degli Studi Di Cagliari**, the receipt and sufficiency of which are hereby acknowledged, I, PAULO LACOLLA, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto **Universita Degli Studi Di Cagliari**, in and for the United States and its territories and for foreign countries, the entire right, title and interest in and to said provisional application and said application for United States Letters Patent, in and to the invention therein set forth and in and to any patent which may issue on said application for United States Letters Patent or any application, reissue, renewal, division, continuation or continuation-in-part thereof; or any foreign counterpart thereof or any other application that claims priority to the above-application, and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 20 day of

JUNE, 2001.



PAULO LACOLLA



Witness

(Dott.ssa Orsola Macis)